INTRODUCTION
Although white adipose tissue (WAT) serves as a repository for fatty acids, it also plays a crucial role in regulating overall energy homeostasis (Spiegelman and Flier, 2001 ). Either too little or too much WAT contributes to metabolic abnormalities that include hyperlipidemia, insulin resistance, and type 2 diabetes. Thus, maintaining the appropriate amount of WAT is crucial for optimal health.
Peroxisome proliferator-activated receptor g (PPARg) is a member of the nuclear receptor family of ligand-activated transcription factors that is highly expressed in WAT (Chawla et al., 1994; Tontonoz et al., 1994a) , where it is required for adipocyte differentiation Tontonoz et al., 1994b) . PPARg exists as two isoforms, PPARg1 and PPARg2, with PPARg2 containing an additional 30 amino acids at its amino terminus (Tontonoz et al., 1994a) . PPARg cooperates with the CCAAT/enhancer-binding protein (C/EBP) family of transcription factors to regulate adipogenesis. C/EBPb and C/EBPd are present early during adipogenesis and induce PPARg expression (Cao et al., 1991; Wu et al., 1995 Wu et al., , 1996 Wu et al., , 1999 Yeh et al., 1995) . C/EBPa is expressed later and together with PPARg governs the adipocyte-specific pattern of gene expression (Lefterova et al., 2008; Tontonoz et al., 1994b; Wu et al., 1998) . Although the identity of the endogenous PPARg ligand is unknown, PPARg is activated by various fatty acids and fatty acid metabolites as well as by the thiazolidinedione (TZD) class of insulin-sensitizing drugs, which include rosiglitazone and pioglitazone (Tontonoz and Spiegelman, 2008; Willson et al., 2001 ). PPARg activity is also regulated by posttranslational modification, including phosphorylation and sumoylation. Phosphorylation of PPARg2 at S112 by MAP kinases represses its transcriptional activity by inhibiting ligand binding and altering cofactor recruitment (Adams et al., 1997; Hu et al., 1996; Shao et al., 1998) . Phosphorylation of PPARg2 at S273 by CDK5 does not alter its adipogenic capacity but dysregulates numerous genes involved in obesity (Choi et al., 2010) . Sumoylation of PPARg2 at K107 blocks its transcriptional activity (Floyd and Stephens, 2004; Ohshima et al., 2004; Yamashita et al., 2004) , possibly by promoting corepressor recruitment. In macrophages, sumoylation of PPARg2 at K395 results in its recruitment to the promoters of inflammatory genes, where it inhibits transcription by preventing clearance of corepressor complexes (Pascual et al., 2005) .
Fibroblast growth factor-21 (FGF21) is an atypical member of the FGF family that functions as a hormone to regulate carbohydrate and lipid metabolism. FGF21 was first shown to regulate metabolism in 3T3-L1 adipocytes, where it stimulated glucose uptake (Kharitonenkov et al., 2005) . When administered pharmacologically to obese, insulin-resistant rodents and monkeys, FGF21 increased energy expenditure, insulin sensitivity, and weight loss, and normalized carbohydrate and lipid parameters (Berglund et al., 2009; Coskun et al., 2008; Kharitonenkov et al., 2005 Kharitonenkov et al., , 2007 Xu et al., 2009) . FGF21 is strongly induced in liver in response to fasting or ketogenic diet (Badman et al., 2007; Inagaki et al., 2007; Lundå sen et al., 2007) . Consistent with a role in the adaptive fasting response, FGF21 stimulated hepatic ketogenesis and gluconeogenesis in lean mice (Potthoff et al., 2009) , and FGF21-transgenic mice were growth inhibited and sensitized to the hibernation-like state of torpor (Inagaki et al., 2007 (Inagaki et al., , 2008 . Mechanistically, FGF21 activates cell signaling by binding to a heteromeric cell-surface receptor tyrosine kinase complex composed of b-Klotho and a conventional FGF receptor (FGFR), with FGFR1c being the preferred isoform for FGF21 Suzuki et al., 2008) . Both b-Klotho and FGFR1c are abundantly expressed in WAT (Fon Tacer et al., 2010; Kurosu et al., 2007) , where FGF21-regulated genes are involved in a variety of metabolic processes including lipogenesis, lipolysis, and fatty acid oxidation (Coskun et al., 2008; Xu et al., 2009 ). Based upon these findings, it was proposed that FGF21 induces futile cycling and energy expenditure in WAT (Coskun et al., 2008) .
During fasting, FGF21 expression in liver is controlled by PPARa, and pharmacologic administration of PPARa agonists (e.g., the fibrate class of hypolipidemic drugs) induces hepatic expression of FGF21 (Badman et al., 2007; Inagaki et al., 2007; Lundå sen et al., 2007) . However, FGF21 is also induced by PPARg agonists, including TZDs, in WAT and isolated adipocytes (Muise et al., 2008; Wang et al., 2008; Zhang et al., 2008) . Although FGF21 and rosiglitazone were shown to cooperate in promoting differentiation and glucose uptake in 3T3-L1 adipocytes (Moyers et al., 2007) , to our knowledge, the functional relationship between TZDs and FGF21 has not been explored in vivo. Here, we show that FGF21 acts in an autocrine fashion in WAT to regulate PPARg activity, to enhance adipogenesis, and to contribute to both the therapeutic and side effects of TZDs. These studies reveal a previously unrecognized facet of FGF21 biology.
RESULTS

FGF21 Is Induced in WAT by Feeding
A previous study showed that Fgf21 is induced by rosiglitazone in WAT of wild-type (WT) and db/db mice (Muise et al., 2008) . Consistent with these findings, FGF21 mRNA and protein levels were induced by rosiglitazone in WAT but not liver of WT mice ( Figures 1A-1D ). Conversely, FGF21 mRNA and protein concentrations were increased by the PPARa agonist, GW7647, in liver but not WAT ( Figures 1A-1D) . Notably, whereas GW7647 markedly increased plasma FGF21 concentrations, rosiglitazone had no effect ( Figure 1E) . In experiments performed with isolated adipocytes, rosiglitazone but not GW7647 increased both FGF21 mRNA levels and protein concentrations in the media ( Figure S1 available online). Taken together, these data suggest that FGF21 is secreted from WAT but acts locally in an autocrine or paracrine fashion instead of entering the circulation.
To determine whether Fgf21 is induced in WAT by diet, Fgf21 mRNA levels were measured at 4 hr intervals in WAT and liver from mice restricted to feeding during a 4 hr period in the middle of the dark cycle. As expected, Fgf21 expression was highest in liver just prior to feeding ( Figure 1F ). In contrast, Fgf21 expression in WAT was very low during fasting but spiked 4 hr after feeding to an absolute level comparable to that seen in liver of fasted mice ( Figure 1F ). Thus, Fgf21 is induced in WAT by either TZD treatment or feeding. Under these conditions we saw no significant changes in the levels of circulating FGF21 (data not shown), which is consistent with increases in blood FGF21 concentrations requiring fasting for 24 hr or more (Muise et al., 2008) .
FGF21-KO Mice Have Mild Lipodystrophy
Given the regulation of Fgf21 in WAT, we examined whether FGF21 knockout (KO) mice have an adipose tissue phenotype. Although FGF21-KO mice had no change in body mass or fluid mass, they had a significant decrease in total fat mass and a significant increase in lean mass (Figures 2A-2D ). There was no difference in food intake between WT and FGF21-KO mice (data not shown). Consistent with these findings, FGF21-KO mice had significantly reduced amounts of epididymal, subcutaneous, mesenteric, retroperitoneal, and interscapular brown adipose tissue (BAT) ( Figure 2E ). There was no difference in the DNA content of epididymal WAT from WT and FGF21-KO mice ( Figure 2F ), indicating that the decreased adiposity was a consequence of smaller adipocytes rather than a decrease in adipocyte number. This difference in adipocyte size was confirmed by histomorphometry (Figures 2G and 2H) . Similar effects on fat mass, lean mass, and epididymal, subcutaneous, and retroperitoneal adipose depot mass were seen in FGF21-KO mice crossed into the C57Bl/6 background ( Figures S2A-S2E ). We note that two other groups reported increased adiposity in FGF21-KO mice (Badman et al., 2009; Hotta et al., 2009) . A possible explanation for this discrepancy is that the diets used by these groups contained soy, whereas ours did not.
FGF21 Enhances Adipocyte Differentiation
To determine whether the adipose tissue phenotype was cell autonomous, we examined the differentiation of preadipocytes derived from WT and FGF21-KO mice. Fgf21 mRNA levels were low but detectable in WT preadipocytes prior to differentiation ( Figure 3A ). Fgf21 expression decreased during the first day of differentiation but then rose steadily over the 8 day differentiation protocol. The mRNA encoding b-Klotho (Klb), an essential component of the FGF21 receptor Suzuki et al., 2008) , was virtually undetectable until day 4 of differentiation and then rose throughout the differentiation period ( Figure 3A) . Interestingly, Klb mRNA levels were lower in FGF21-KO adipocytes but restored by inclusion of recombinant FGF21 in the differentiation medium ( Figure 3A) . Expression of Fgfr1c, which encodes the other subunit of the FGF21 receptor, decreased during the early stages of differentiation and was unaffected by the absence of FGF21 ( Figure 3A ). These data suggest that FGF21 signaling initiates between days 2 and 4 of adipocyte differentiation.
We next examined the temporal pattern of expression for a panel of genes that is expressed during the differentiation process. The expression pattern for Cebpb and Cebpd, which play important roles in the early stages of adipocyte differentiation (Cao et al., 1991; Wu et al., 1999; Yeh et al., 1995) , was similar between WT and FGF21-KO adipocytes and unaffected by treatment with recombinant FGF21 ( Figure 3A) . In contrast the induction of Cebpa and Pparg mRNAs was delayed in FGF21-KO adipocytes. Whereas Pparg expression was efficiently restored by recombinant FGF21, Cebpa expression was not ( Figure 3A ). The mRNAs encoding the fatty acid binding protein, aP2, and the lipogenic proteins solute carrier family 25, member 1 (SLC25A1), ATP citrate lyase (ACLY), malic enzyme (ME1), acetyl-CoA carboxylase a (ACACA), fatty acid synthase (FASN), and diacylglycerol O-acyltransferase 2 (DGAT2) had similar expression patterns: the level of each was reduced in FGF21-KO adipocytes and at least partially restored by treatment with recombinant FGF21 ( Figure 3A ). For Cebpa, Pparg, and most of the lipogenic genes, reduced expression was first observed at day 4 of differentiation, consistent with when Klb mRNA first appears in WT adipocytes ( Figure 3A ). Phosphoenolpyruvate carboxykinase (Pck1), which was induced only at day 8 of differentiation, was also reduced in FGF21-KO adipocytes and partially restored by recombinant FGF21 (Figure 3A) . In agreement with the lipogenic gene expression data, lipid accumulation was reduced in FGF21-KO adipocytes and restored to WT levels in the presence of recombinant FGF21 ( Figure 3B ).
FGF21 Stimulates PPARg Transcriptional Activity
The impaired differentiation and lipid accumulation in FGF21-KO adipocytes suggested that FGF21 might regulate PPARg activity. To examine this, WT and FGF21-KO adipocytes were differentiated in the presence or absence of rosiglitazone. As expected, rosiglitazone treatment increased lipogenic gene expression and lipid accumulation in WT adipocytes (Figures 4A and 4B) . However, the stimulatory effects of rosiglitazone were attenuated in FGF21-KO adipocytes. Inclusion of recombinant FGF21 rescued the effect of rosiglitazone on gene (A-E) Two-month-old male C57Bl/6 mice fed regular chow were treated for 17 hr with GW7647 (10 mg/kg), rosiglitazone (Rosi; 10 mg/kg), or vehicle (1% methylcellulose). Fgf21 mRNA in epididymal (e) WAT (A) and liver (B) was measured by qRT-PCR. C t values are indicated. FGF21 protein concentrations in eWAT (C), liver (D), and plasma (E) were measured by ELISA. For (A)-(E), n = 4/group. (F) Eight-to ten-week-old male C57Bl/6 mice were food entrained for 2 weeks by restricting their access to chow to a 4 hr period in the middle of the dark cycle. Tissues were collected at 4 hr intervals over a 24 hr period, and Fgf21 mRNA was analyzed by qRT-PCR. Data were normalized to Fgf21 mRNA levels at their lowest point (16 hr for WAT, 4 hr for liver) and are double plotted (n = 6/group). Error bars represent the mean ± standard error of the mean (SEM) (a, p < 0.05 versus vehicle; b, p < 0.01 versus vehicle). See also Figure S1 .
expression and lipid accumulation in the FGF21-KO adipocytes (Figures 4A and 4B) .
Total PPARg protein levels were unchanged in primary adipocytes either lacking endogenous FGF21 or treated with recombinant FGF21 ( Figure 4C ). Likewise, there was no change in the level of PPARg phosphorylated at S112 under these conditions ( Figure S3A) . Notably, however, there was a significant increase in sumoylated PPARg in FGF21-KO adipocytes ( Figure 4C ). This increase in PPARg sumoylation was reversed by including recombinant FGF21 in the media ( Figure 4C ). In agreement with these in vitro results, there was a significant increase in PPARg sumoylation in WAT from FGF21-KO mice ( Figure 4D ) and a corresponding decrease in PPARg target gene expression ( Figure 4E ). There was no change in PPARg phosphorylation at either S112 or S273 in WAT from FGF21-KO mice ( Figures S3A and S3B ). Similar effects on PPARg sumoylation and target gene expression were seen in FGF21-KO mice crossed onto the C57Bl/6 background ( Figures S3C  and S3D ). Taken together, the in vitro and in vivo data suggest that FGF21 increases PPARg transcriptional activity by suppressing its sumoylation.
PPARg can be sumoylated at K107 and K395 with different transcriptional outcomes (Floyd and Stephens, 2004; Ohshima (A-E) The mass of various body depots was measured in 2-month-old male wild-type (WT) and FGF21-KO mice fed regular chow. For (E), adipose tissue mass was measured and normalized to body weight for epididymal (e), subcutaneous (sc), mesenteric (m), retroperitoneal (rp), and BAT depots. For (A)-(D), n = 11-12/group; for (E), n = 6/ group. (F) DNA content of eWAT pads was measured and normalized to body mass (n = 4/group). (G) Representative hematoxylin and eosin-stained eWAT sections from WT and FGF21-KO mice. Scale bars, 100 mM. (H) Adipocyte size was measured using images of eWAT sections and ImageJ software (n > 150 cells/group). Error bars represent the mean ± SEM (a, p < 0.05 versus WT; b, p < 0.01 versus WT; c, p < 0.005). See also Figure S2 . Pascual et al., 2005; Yamashita et al., 2004) . To determine at which position PPARg is sumoylated in FGF21-KO adipocytes, the sumoylation sites were mutated either singly or together in the context of a 3xFlag-tagged PPARg, and the tagged PPARg mutants introduced into FGF21-KO adipocytes. Mutating K107 (K107R) but not K395 (K395R) blocked PPARg sumoylation as measured by immunoprecipitation with a Flag antibody followed by western blot analysis for the $80 kDa sumoylated PPARg protein with either SUMO1 or PPARg antibodies (Figures 4F and S3E) . Sumoylation at K107 inhibits PPARg activity (Floyd and Stephens, 2004; Ohshima et al., 2004; Yamashita et al., 2004) . Thus, these data suggest that in the absence of FGF21, PPARg transcriptional activity is impaired by sumoylation at K107.
We investigated whether introduction of the PPARg-K107R sumoylation mutant into FGF21-KO preadipocytes would reverse their impaired differentiation phenotype. PPARg-K395R was also included in these experiments as a control. Preadipocytes derived from WT and FGF21-KO mice were infected with lentiviruses expressing either WT PPARg, the K107R or K395R sumoylation mutants or a control GFPexpressing virus. As expected, adipocytes from FGF21-KO mice infected with control (GFP) lentivirus showed decreased expression of Slc25a1, Acly, Me1, Acaca, Fasn, Dgat2 , and Pck1 at the end of the differentiation period compared to adipocytes from WT mice ( Figure 4G) . Expression of these genes was rescued in FGF21-KO adipocytes by PPARg-K107R, but not WT PPARg or PPARg-K395R (Figure 4G ). These data indicate that increased sumoylation of PPARg in FGF21-KO adipocytes contributes to their altered phenotype.
FGF21-KO Mice Are Refractory to Rosiglitazone
If FGF21 is required for full PPARg activity, then FGF21-KO mice should be resistant to the actions of TZDs. To test this prediction, groups of diet-induced obese (DIO) WT and FGF21-KO mice were treated with rosiglitazone or vehicle for 14 days. As expected, rosiglitazone induced FGF21 mRNA and protein in WAT of WT mice ( Figures 5A and 5B) . In contrast, rosiglitazone treatment decreased hepatic Fgf21 mRNA levels and had little or no effect on hepatic FGF21 protein levels ( Figures 5C and 5D ). Circulating FGF21 concentrations were decreased by rosiglitazone treatment ( Figure 5E ). These data provide further evidence that FGF21 synthesized in WAT acts in an autocrine or paracrine manner rather than circulating as a hormone.
As expected, rosiglitazone treatment significantly reduced plasma glucose and insulin concentrations in WT mice (Figure 5F ). Although plasma insulin and glucose levels trended lower in rosiglitazone-treated FGF21-KO mice, these differences were not statistically significant ( Figure 5F ). Importantly, rosiglitazone treatment improved glucose disposal in glucose and insulin tolerance tests in WT but not FGF21-KO mice ( Figures  5G and 5H) . In glucose tolerance tests, rosiglitazone decreased plasma insulin concentrations in both WT and FGF21-KO mice ( Figure 5I ). This result was surprising in the FGF21-KO mice given the lack of an effect of rosiglitazone treatment on glucose concentrations. Notably, peak insulin concentrations were significantly higher in WT mice compared to FGF21-KO mice ( Figure 5I ), suggesting that FGF21-KO mice have impaired insulin secretion. This is consistent with the finding that FGF21 stimulated insulin secretion in isolated rodent islets (Wente et al., 2006) . Plasma nonesterified fatty acid and triglyceride concentrations and hepatic triglyceride concentrations were either significantly increased or trended upward in FGF21-KO mice compared to WT mice (Figures 5J-5L ). Rosiglitazone (C) Sumoylated and total PPARg protein levels were measured in WT and FGF21-KO adipocytes differentiated for 8 days and treated with vehicle or FGF21 (200 ng/ml) for 4 hr prior to harvest. Sumoylated PPARg was detected by immunoprecipitation with a SUMO1 antibody followed by western blot analysis with a PPARg antibody. Phosphorylated and total PPARg and b-actin were detected by western blot. Top panel shows quantification by densitometry of sumoylated PPARg normalized to total PPARg for an experiment performed in triplicate (a, p < 0.05). Bottom panel illustrates representative western blots. (D) Sumoylated and total PPARg protein levels were measured as in (C) in epididymal WAT extracts from 2-to 3-month-old male WT and FGF21-KO mice fed regular chow and killed in the fed state. Top panel shows quantification by densitometry of sumoylated PPARg normalized to total PPARg for WT and KO mice (n = 4/group) (a, p < 0.05). Bottom panel illustrates western blots for pooled samples. decreased these parameters in FGF21-KO mice to levels comparable to those in rosiglitazone-treated WT mice. We conclude that FGF21 is required for some but not all of the metabolic effects of rosiglitazone in DIO mice. We further conclude that some of these effects are likely to involve FGF21 acting on tissues other than WAT, including pancreas.
Two well-established side effects of TZDs are increased adiposity and fluid retention. Although rosiglitazone did not significantly change body mass in DIO WT or FGF21-KO mice, it significantly increased fat mass and fluid mass and decreased lean mass in WT mice (Figures 5M-5P) . Notably, the effects of rosiglitazone on fat mass, lean mass, and fluid mass were absent in FGF21-KO mice (Figures 5N-5P) . Thus, FGF21 is required for both beneficial and adverse effects of rosiglitazone.
We next compared WAT from DIO WT and FGF21-KO mice treated with rosiglitazone or vehicle. Phosphorylation of Akt at S473 in WAT was higher in WT mice than FGF21-KO mice after treatment with either rosiglitazone or rosiglitazone plus insulin ( Figure S4 ), indicating that the absence of FGF21 impairs insulin sensitivity in adipose. As expected, rosiglitazone treatment decreased adipocyte size in WT mice ( Figure 6A ). Interestingly, under DIO conditions, adipocytes were larger in FGF21-KO mice. Furthermore, in DIO FGF21-KO mice, rosiglitazone treatment was less effective at decreasing adipocyte size, and consequently, the adipocytes remained significantly larger than those from WT mice treated with rosiglitazone ( Figure 6A ). As was observed in chow-fed mice, sumoylated PPARg levels in WAT were markedly increased in DIO FGF21-KO mice compared to WT mice ( Figure 6B ). Consistent with these findings, microarray analysis revealed large clusters of genes that were either upregulated or downregulated in response to rosiglitazone treatment in WT mice, but not in FGF21-KO mice (Figure 6C) . Loss of rosiglitazone responsiveness in FGF21-KO WAT was confirmed for a subset of PPARg target genes by qRT-PCR ( Figure 6D ). For reasons that are not known, basal expression of Slc25a1 and Fasn was elevated in WAT of FGF21-KO mice ( Figure 6D ). Pck1 expression was significantly reduced in FGF21-KO WAT and unresponsive to rosiglitazone treatment ( Figure 6D ). Analysis of adipokines revealed the expected decrease in Tnfa expression in WAT of WT mice treated with rosiglitazone ( Figure 6E ). This response was absent in FGF21-KO mice ( Figure 6E ). Although plasma adiponectin levels increased in response to rosiglitazone administration in both WT and FGF21-KO mice, this induction was significantly attenuated in FGF21-KO mice ( Figure 6F ). Taken together, these data show that the actions of rosiglitazone are compromised in DIO FGF21-KO mice.
DISCUSSION
In this report we demonstrate an important role for FGF21 in regulating PPARg activity in WAT. FGF21 was previously shown to be induced by PPARg agonists in WAT and to cooperate with rosiglitazone in promoting differentiation and glucose uptake in 3T3-L1 adipocytes in vitro (Moyers et al., 2007; Muise et al., 2008; Wang et al., 2008; Zhang et al., 2008) . We now show that lean mice lacking FGF21 have decreased PPARg activity in WAT and corresponding reductions in WAT mass and adipocyte size. We further show that obese, insulin-resistant mice lacking FGF21 are refractory to the actions of rosiglitazone, including both beneficial and adverse effects. We conclude that the actions of FGF21 and PPARg are fundamentally intertwined in WAT.
A surprising result from our studies is that rosiglitazonemediated induction of FGF21 in WAT does not cause a corresponding increase in circulating FGF21 in either lean or DIO mice. In DIO mice, plasma FGF21 levels decreased in parallel with reduced Fgf21 mRNA in liver. In agreement with a previous study , we show that rosiglitazone treatment of isolated adipocytes increased FGF21 in the media, demonstrating that FGF21 is secreted from adipocytes in vitro. A parsimonious explanation for these data is that FGF21 is secreted from adipocytes but is unable to reach the circulation, perhaps due to interactions with the WAT extracellular matrix. Thus, FGF21 is restricted to acting in an autocrine or paracrine manner in WAT, much like conventional FGFs. FGF21 is also proposed to act through an autocrine mechanism in exocrine pancreas and liver Johnson et al., 2009) . In recent human studies, rosiglitazone treatment had no effect on circulating FGF21 concentrations in subjects who were either healthy or had impaired glucose tolerance (Christodoulides et al., 2009; Mai et al., 2009 ), but significantly decreased circulating FGF21 in patients with type 2 diabetes (Li et al., 2009a) . This latter study together with the finding that rosiglitazone induces FGF21 expression in primary cultures of human adipocytes suggest that FGF21 is regulated similarly in mice and man. However, whereas one group reported that FGF21 mRNA is present in human WAT , another group detected little or no FGF21 mRNA in human WAT samples (Dushay et al., 2010) . Additional studies will be required to determine the relevance of FGF21 expression in human WAT in both physiologic and pharmacologic contexts.
Previous studies showed that sumoylation of PPARg at K107 represses its transcriptional activity in vitro (Floyd and Stephens, 2004; Ohshima et al., 2004; Yamashita et al., 2004) . However, the (E) Gene expression was measured by qRT-PCR in the epididymal WAT of 2-to 3-month-old male WT and FGF21-KO mice killed during the fed state (n = 6-7/group) (a, p < 0.05 versus WT; b, p < 0.01 versus WT). (F) Flag-tagged PPARg2, PPARg2-K107R, PPARg2-K395R, or PPARg2-K107R/K395R was introduced into primary FGF21-KO adipocytes by transfection, and its sumoylation was measured by immunoprecipitation with a Flag antibody followed by western blot analysis with either a SUMO1 or PPARg antibody. Input levels of Flag-tagged PPARg and the PPARg mutants were determined by western blot analysis with a Flag antibody. Data were quantified by densitometry (a, p < 0.05 versus WT). (G) Gene expression was measured by qRT-PCR in WT and FGF21-KO stromal vascular fraction preadipocytes transduced with lentiviruses expressing PPARg2, PPARg2-K107R, PPARg2-K395R, or GFP control and differentiated for 4 days. PPARg2, PPARg2-K107R, and PPARg2-K395R were expressed at comparable levels ( Figure S3E ). Data are plotted as relative mRNA expression in FGF21-KO adipocytes compared to WT adipocytes (a, p < 0.05 versus GFP; b, p < 0.01 versus GFP). Error bars represent the mean ± SEM. See also Figure S3 . in vivo relevance of this PPARg sumoylation event remained unclear. We now show that the absence of FGF21 causes a marked increase in sumoylated PPARg in WAT in vivo. This increase in sumoylated PPARg corresponds to a decrease in the expression of PPARg target genes. Our in vitro studies with FGF21-KO adipocytes show that PPARg sumoylation occurs at K107. We further show that the effect of FGF21 deficiency on adipocyte differentiation can be overcome by expressing a PPARg K107 mutant, strongly suggesting that increased PPARg sumoylation contributes to the FGF21-KO phenotype. Precisely how sumoylation blocks the transcriptional activity of PPARg remains unclear, although in vitro studies suggest that it may involve the recruitment of corepressor proteins (Yamashita et al., 2004) . Notably, sumoylation of PPARg is reduced by mutating the adjacent phosphorylation site at S112 (Yamashita et al., 2004) , which also increases PPARg transcriptional activity (Adams et al., 1997; Hu et al., 1996; Shao et al., 1998) . However, we did not see increased PPARg S112 phosphorylation in FGF21-KO WAT, suggesting that phosphorylation and sumoylation are not coupled in this context.
Based on the data in sum, we propose a feed-forward regulatory model wherein PPARg induces FGF21 in WAT, which then acts in an autocrine or paracrine manner to block PPARg sumoylation ( Figure 6G ). The net effect is an increase in PPARg activity in mid-to late-stage preadipocytes and mature adipocytes, which express both b-Klotho and FGFR1c. We further propose that FGF21 contributes to the antidiabetic TZD response in adipose tissue through at least two PPARg-dependent mechanisms: by increasing the number of small, metabolically active adipocytes, and by raising adiponectin levels in the circulation. Although DIO FGF21-KO mice were refractory to rosiglitazone treatment, we note that the drug response was not eliminated. Rosiglitazone still significantly decreased plasma and hepatic triglyceride concentrations and decreased plasma insulin concentrations in glucose tolerance tests in FGF21-KO mice. Thus, rosiglitazone has FGF21-independent effects.
Our finding that FGF21 is required for rosiglitazone to increase adiposity and fluid mass is puzzling for two reasons. First, whereas the adiposity findings are consistent with FGF21 expression and induction by TZDs in WAT, they appear at odds with pharmacologic studies in which exogenous FGF21 administration causes significant weight loss in obese animals (Kharitonenkov et al., 2005 . We suggest that this may reflect the difference between endogenous FGF21 acting in a paracrine fashion on WAT alone versus exogenous FGF21 acting coordinately on multiple tissues including liver, where FGF21 stimulates fatty acid oxidation and ketogenesis (Badman et al., 2007; Inagaki et al., 2007; Potthoff et al., 2009) , BAT, where FGF21 increases thermogenesis (Hondares et al., 2010) , and the central nervous system, where FGF21 enhances insulin sensitivity (Sarruf et al., 2010) . Thus, pharmacologic administration of FGF21 may provide a means of obtaining the beneficial, insulin-sensitizing effects of PPARg agonists without causing weight gain. A second puzzle is how the absence of FGF21 influences TZD-mediated increases in fluid mass because neither FGF21 nor its coreceptor, b-Klotho, appears to be expressed in the kidney (Fon Tacer et al., 2010) , where activation of PPARg decreases urinary sodium excretion and increases fluid retention (Guan et al., 2005; Zhang et al., 2005) . However, we note that the effects of TZDs on fluid retention are not entirely eliminated by removing PPARg in kidney , suggesting that other tissues are involved. To our knowledge, it remains to be determined how FGF21 impacts TZD-mediated changes in fluid mass.
Why might a hormone that elicits diverse aspects of the starvation response-presumably by acting on multiple tissuesbe selectively induced in WAT in the fed state? One possibility is that FGF21 regulates pathways in WAT that are important under both fed and fasted conditions. A notable example of this is triglyceride synthesis. In the fed state, glucose and fatty acids are stored as triglyceride in WAT. However, triglyceride synthesis also plays an important role during fasting, when $75% of fatty acids released by lipolysis are reabsorbed and re-esterified by WAT and other tissues, including liver (Reshef et al., 2003) . This ''triglyceride/fatty acid cycle'' is believed to serve as a mechanism for controlling the delivery of substrates to tissues, including fatty acids and glycerol to the liver for ketogenesis and gluconeogenesis, respectively (Reshef et al., 2003) . Our finding that FGF21 regulates genes such as Dgat2 and Pck1 is consistent with the notion that it modulates triglyceride homeostasis in both the fed and fasted states. A role for FGF21 in controlling the triglyceride/fatty acid cycle may also explain why FGF21 has alternately been reported to stimulate (Inagaki et al., 2007) or to repress lipolysis in white adipocytes (Arner et al., 2008; Li et al., 2009b) . Although on the one hand FGF21 induces lipases such as adipose triglyceride lipase and hormone-sensitive lipase that are involved in triglyceride hydrolysis and mobilization (Coskun et al., 2008; Inagaki et al., 2007) , it also induces genes that are involved in triglyceride synthesis. Thus, the net effect of FGF21 on fatty acid homeostasis likely depends on the precise physiologic context. A role for FGF21 in modulating the triglyceride/fatty acid cycle is consistent with the elevated circulating fatty acid levels that occur in FGF21-KO mice during fasting (Hotta et al., 2009; Potthoff et al., 2009 ).
In summary we describe an unexpected role for FGF21 in white adipocytes. We conclude that FGF21 has two disparate physiologic functions: as an endocrine hormone secreted by the liver to coordinate the adaptive response during starvation; and as an autocrine or paracrine factor induced in WAT during the fed state to regulate adipocyte function.
EXPERIMENTAL PROCEDURES
Animal Experiments FGF21-KO mice were generated as described (Potthoff et al., 2009 ), including two generations of heterozygous crosses, and maintained on a mixed C57Bl/6 3 129 genetic background as separate WT (Fgf21 +/+ ) and homozygous KO (Fgf21 À/À ) breeding lines. For pure strain studies, FGF21-KO mice were backcrossed for six generations onto the C57Bl/6 background. Mice were maintained on a standard chow diet containing 4% fat (Harlan Teklad Global Diet; #2916). All experiments were performed with male mice. DIO mice were fed a high-fat diet containing 60% kcal from fat (Research Diets; #D12492). Oral glucose tolerance tests were performed on groups of DIO mice treated with rosiglitazone or vehicle for 1 week. One week later, after being maintained on the high-fat and rosiglitazone Figure 6 . FGF21 Is Required for Rosiglitazone Effects in WAT (A-E) Two-to three-month-old WT and FGF21-KO mice were fed a high-fat diet for 10 weeks. During the last 2 weeks, groups of mice were administered rosiglitazone (Rosi; 10 mg/kg) or vehicle (1% methylcellulose). The following parameters were measured in epididymal WAT: (A) adipocyte size was determined using ImageJ software (n > 250 cells/group) (a, p < 0.05; b, p < 0.01; c, p < 0.001). (B) Sumoylated PPARg was detected in epididymal WAT extracts by either immunoprecipitation with a SUMO1 antibody followed by western blot analysis with a PPARg antibody or the reverse. Total PPARg and b-actin were measured by western blot analysis. For each lane, WAT extracts were pooled from four mice. Numbers represent relative levels quantified by densitometry. (C) Microarray analysis resulted in the identification of 545 genes that were significantly changed in response to rosiglitazone treatment in epididymal WAT from either wild-type or FGF21-KO mice killed in the fed state. A heat map of the data is shown. R, rosiglitazone. (D) Gene expression was measured by qRT-PCR (n = 5-6/group) (a, p < 0.05 versus WT, vehicle). (E) Tnfa mRNA was measured by qRT-PCR (n = 5-6/group) (a, p < 0.05 versus WT, vehicle). (F) Plasma adiponectin concentrations were measured by ELISA (n = 11-14/group) (c, p < 0.001). Error bars represent the mean ± SEM. (G) Model of the PPARg-FGF21 regulatory pathway in adipose tissue.
regimen, insulin tolerance tests were performed on these same groups of mice. All animal experiments were approved by the Institutional Animal Research Advisory Committee of the University of Texas Southwestern Medical Center at Dallas.
Body Composition Analysis
Body composition was measured using a Bruker Minispec mq10 NMR.
Primary Adipocyte Differentiation Assays
Primary preadipocytes were isolated from postnatal day (P) 4 WT and FGF21-KO mice, grown to confluency, and differentiated in media containing high-glucose DMEM plus 10% FBS, 10 mg/ml insulin, 0.5 mM isobutylmethylxanthine, and 0.25 mM dexamethasone.
Microarray Analysis RNA prepared from epididymal WAT from DIO WT and FGF21-KO mice treated with rosiglitazone or vehicle for 14 days was reverse transcribed into cRNA, biotin-UTP labeled, and hybridized to the Illumina mouseRefseq-8v2 Expression BeadChip.
Statistical Analysis
Statistical analyses were performed using Microsoft Excel 2007. Comparisons of two groups were performed using Student's t test. p < 0.05 was considered significant.
SUPPLEMENTAL INFORMATION
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